It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company ...
Discover historical prices for LXRX stock on Yahoo Finance. View daily, weekly or monthly format back to when Lexicon Pharmaceuticals, Inc. stock was issued.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback